FDA Accepts Unicycive’s NDA for Oxylanthanum Carbonate, PDUFA Date June 2025
FDA Accepts Unicycive’s NDA for Oxylanthanum Carbonate, PDUFA Date June 2025 Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, ...
FDA Extends PDUFA Date for Neurotech’s NT-501 Eye Cell Therapy Implant
FDA Extends PDUFA Date for Neurotech’s NT-501 Eye Cell Therapy Implant Neurotech Pharmaceuticals' eye cell therapy implant has faced a delay, as the US Food and Drug Administration (FDA) extended the ...